Download presentation
Presentation is loading. Please wait.
Published byἭλιος Πρωτονοτάριος Modified over 6 years ago
1
a. Good prognosis Poor prognosis Metastasis b. Good prognosis Metastatic variants Metastasis c. Metastasis Good prognosis Poor prognosis
2
a. Separate origins Normal tissue Poor prognosis b. Clonal progression BUT - are the tumors homogeneous even for primary tumor growth
3
CD44+ / B38.1+ CD24lo Lin-
4
Lin- / CD44+ / CD24lo Cells are tumorigenic They comprise minority of cells in tumor They don’t have a growth advantage
5
Lin- / CD44+ / CD24lo cells are tumorigenic
Sorting for ESA+ further enriches - only a few % of cells in tumor.
6
T1 200 P1 sorted P2 T2 1000 Lin- / CD44+ / CD24lo cells regenerate the mixture of cell types thru 4 passages
7
Therefore tumors contain rare, self-renewing cells that
are tumorigenic and can regenerate multiple cell types That is, tumor stem cells or tumor-initiating cells. Most cells in the tumor lack these properties. Therapy should be directed at the subset, not the majority.
8
Micrometastases Present in 30% of BrCa patients but only 50% eventually progress to clinically evident tumors within 5 years Are they a mix of rare malignant seeds and other non-malignant seeds? Or do they reflect seeding of a homogeneous set of premalignant cells with a uniform probability of forming frank tumors?
11
Good prognosis Stromal response Metastatic variants Poor prognosis Metastasis
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.